BACKGROUND: Chronic inflammation may participate in the pathogenesis of insulin resistance, type 2 diabetes, and cardiovascular disease and may be a common denominator that links obesity to these disease states. CONTENT: Epidemiologic studies have linked inflammatory biomarkers to incident diabetes and cardiovascular disease risk. Cellular and animal studies have provided support to the idea that inflammation mediates these disease processes, providing impetus to pharmacologically target these pathways for disease treatment and prevention. We review clinical strategies to target inflammation, with a focus on the antiinflammatory and antihyperglycemic effects of salicylates. SUMMARY: The evolving concept of diet-induced obesity driving insulin resistance, type 2 diabetes, and cardiovascular disease through immunologic processes provides new opportunities for the use of antiinflammatory strategies to correct the metabolic consequences of excess adiposity.
BACKGROUND:Chronic inflammation may participate in the pathogenesis of insulin resistance, type 2 diabetes, and cardiovascular disease and may be a common denominator that links obesity to these disease states. CONTENT: Epidemiologic studies have linked inflammatory biomarkers to incident diabetes and cardiovascular disease risk. Cellular and animal studies have provided support to the idea that inflammation mediates these disease processes, providing impetus to pharmacologically target these pathways for disease treatment and prevention. We review clinical strategies to target inflammation, with a focus on the antiinflammatory and antihyperglycemic effects of salicylates. SUMMARY: The evolving concept of diet-induced obesity driving insulin resistance, type 2 diabetes, and cardiovascular disease through immunologic processes provides new opportunities for the use of antiinflammatory strategies to correct the metabolic consequences of excess adiposity.
Authors: Andreas Pfützner; Nikolaus Marx; Georg Lübben; Matthias Langenfeld; Daniel Walcher; Thomas Konrad; Thomas Forst Journal: J Am Coll Cardiol Date: 2005-06-21 Impact factor: 24.094
Authors: Takara L Stanley; Markella V Zanni; Stine Johnsen; Sarah Rasheed; Hideo Makimura; Hang Lee; Victor K Khor; Rexford S Ahima; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2010-11-03 Impact factor: 5.958
Authors: Melek C Arkan; Andrea L Hevener; Florian R Greten; Shin Maeda; Zhi-Wei Li; Jeffrey M Long; Anthony Wynshaw-Boris; Giuseppe Poli; Jerrold Olefsky; Michael Karin Journal: Nat Med Date: 2005-01-30 Impact factor: 53.440
Authors: John F Pearson; Chethan Bachireddy; Sangameswaran Shyamprasad; Allison B Goldfine; John S Brownstein Journal: Diabetes Care Date: 2010-07-13 Impact factor: 19.112
Authors: Dolors Serra; Paula Mera; Maria Ida Malandrino; Joan Francesc Mir; Laura Herrero Journal: Antioxid Redox Signal Date: 2012-10-05 Impact factor: 8.401
Authors: David K Scoville; Cindy Yanfei Li; Dongfang Wang; Joseph L Dempsey; Daniel Raftery; Sridhar Mani; Haiwei Gu; Julia Yue Cui Journal: Drug Metab Dispos Date: 2019-05-23 Impact factor: 3.922
Authors: Sergey Filippov; Stephen L Pinkosky; Richard J Lister; Catherine Pawloski; Jeffrey C Hanselman; Clay T Cramer; Rai Ajit K Srivastava; Timothy R Hurley; Cheryl D Bradshaw; Mark A Spahr; Roger S Newton Journal: J Lipid Res Date: 2013-05-24 Impact factor: 5.922